These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16397034)

  • 1. Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients.
    Henrich KO; Fischer M; Mertens D; Benner A; Wiedemeyer R; Brors B; Oberthuer A; Berthold F; Wei JS; Khan J; Schwab M; Westermann F
    Clin Cancer Res; 2006 Jan; 12(1):131-8. PubMed ID: 16397034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allelic variants of CAMTA1 and FLJ10737 within a commonly deleted region at 1p36 in neuroblastoma.
    Henrich KO; Claas A; Praml C; Benner A; Mollenhauer J; Poustka A; Schwab M; Westermann F
    Eur J Cancer; 2007 Feb; 43(3):607-16. PubMed ID: 17222547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAMTA1, a 1p36 tumor suppressor candidate, inhibits growth and activates differentiation programs in neuroblastoma cells.
    Henrich KO; Bauer T; Schulte J; Ehemann V; Deubzer H; Gogolin S; Muth D; Fischer M; Benner A; König R; Schwab M; Westermann F
    Cancer Res; 2011 Apr; 71(8):3142-51. PubMed ID: 21385898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of FLJ10737 and CAMTA1 genes on the commonly deleted region of neuroblastoma at human chromosome 1p36.31-p36.23.
    Katoh M; Katoh M
    Int J Oncol; 2003 Oct; 23(4):1219-24. PubMed ID: 12964007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
    Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
    Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome.
    Brinkschmidt C; Christiansen H; Terpe HJ; Simon R; Lampert F; Boecker W; Dockhorn-Dworniczak B
    Med Pediatr Oncol; 2001 Jan; 36(1):11-3. PubMed ID: 11464859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of chromosome 1p deletions in neuroblastoma.
    Maris JM; Guo C; Blake D; White PS; Hogarty MD; Thompson PM; Rajalingam V; Gerbing R; Stram DO; Matthay KK; Seeger RC; Brodeur GM
    Med Pediatr Oncol; 2001 Jan; 36(1):32-6. PubMed ID: 11464900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell cycle-dependent transcriptional regulation of calmodulin-binding transcription activator 1 in neuroblastoma cells.
    Nakatani K; Nishioka J; Itakura T; Nakanishi Y; Horinouchi J; Abe Y; Wada H; Nobori T
    Int J Oncol; 2004 Jun; 24(6):1407-12. PubMed ID: 15138581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome.
    Oberthuer A; Hero B; Spitz R; Berthold F; Fischer M
    Clin Cancer Res; 2004 Jul; 10(13):4307-13. PubMed ID: 15240516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
    Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B
    BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas.
    Okawa ER; Gotoh T; Manne J; Igarashi J; Fujita T; Silverman KA; Xhao H; Mosse YP; White PS; Brodeur GM
    Oncogene; 2008 Jan; 27(6):803-10. PubMed ID: 17667943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of genomic imprinting at 1p35-36 in neuroblastoma.
    Hogarty MD; Maris JM; White PS; Guo C; Brodeur GM
    Med Pediatr Oncol; 2001 Jan; 36(1):52-5. PubMed ID: 11464906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome.
    Fischer M; Oberthuer A; Brors B; Kahlert Y; Skowron M; Voth H; Warnat P; Ernestus K; Hero B; Berthold F
    Clin Cancer Res; 2006 Sep; 12(17):5118-28. PubMed ID: 16951229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma.
    White PS; Thompson PM; Gotoh T; Okawa ER; Igarashi J; Kok M; Winter C; Gregory SG; Hogarty MD; Maris JM; Brodeur GM
    Oncogene; 2005 Apr; 24(16):2684-94. PubMed ID: 15829979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q.
    McArdle L; McDermott M; Purcell R; Grehan D; O'Meara A; Breatnach F; Catchpoole D; Culhane AC; Jeffery I; Gallagher WM; Stallings RL
    Carcinogenesis; 2004 Sep; 25(9):1599-609. PubMed ID: 15090470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status.
    Westermann F; Henrich KO; Wei JS; Lutz W; Fischer M; König R; Wiedemeyer R; Ehemann V; Brors B; Ernestus K; Leuschner I; Benner A; Khan J; Schwab M
    Clin Cancer Res; 2007 Aug; 13(16):4695-703. PubMed ID: 17652624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Clin Cancer Res; 2003 Oct; 9(13):4835-40. PubMed ID: 14581355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.
    Bown N; Cotterill S; Lastowska M; O'Neill S; Pearson AD; Plantaz D; Meddeb M; Danglot G; Brinkschmidt C; Christiansen H; Laureys G; Speleman F; Nicholson J; Bernheim A; Betts DR; Vandesompele J; Van Roy N
    N Engl J Med; 1999 Jun; 340(25):1954-61. PubMed ID: 10379019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction of in vitro transcribed ENO1 mRNA into neuroblastoma cells induces cell death.
    Ejeskär K; Krona C; Carén H; Zaibak F; Li L; Martinsson T; Ioannou PA
    BMC Cancer; 2005 Dec; 5():161. PubMed ID: 16359544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.